DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03110159 |
|
Recruitment Status :
Recruiting
First Posted : April 12, 2017
Last Update Posted : May 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a pilot, phase 2, prospective, comparative study to evaluate the safety and efficacy of the combination of Levulan® Kerastick® for Topical Solution and blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator (LevulanPDT).
The study hypothesis is that post solid organ transplantation patients, highly susceptible to non-melanoma skin cancer, can be treated safely and effectively through clinical cyclic application of PDT, lessening morbidity and possible mortality for this immunosuppressed patient population.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Skin Cancer Non-melanoma Skin Cancer Sun Damaged Skin Actinic Keratosis | Drug: Levulan® Kerastick® Drug: BLU-U Blue Light Photodynamic Therapy | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Cyclic PDT for the Prevention of Actinic Keratosis and Non Melanoma Skin Cancer in Solid Organ Transplant Recipients |
| Actual Study Start Date : | August 29, 2017 |
| Estimated Primary Completion Date : | January 2022 |
| Estimated Study Completion Date : | January 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Levulan® Kerastick® and blue light illumination
Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds. Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years. |
Drug: Levulan® Kerastick®
Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light Drug: BLU-U Blue Light Photodynamic Therapy 3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
Other Name: blue light illumination |
- Primary prevention of AKs in recently transplanted solid organ recipient [ Time Frame: 3 Years ]Number of AK will be counted for each site using the photographs of the treatment and the control areas. AKs will be graded by thickness.
- Time to occurrence of AKs in recently transplanted solid organ recipient [ Time Frame: 3 Years ]Time to occurrence of AK will be calculated from the first visit to the development of an AK in the treatment areas and in the control areas.
- Primary prevention of NMSC in recently transplanted solid organ recipient [ Time Frame: 3 Years ]Number of NMSC will be counted for each site using the photographs of the treatment and the control areas. NMSC, including basal cell carcinoma, Bowen's disease and squamous cell carcinoma, will be diagnosis and confirmed histologically by biopsy.
- Time to occurrence of NMSC in recently transplanted solid organ recipient [ Time Frame: 3 Years ]Time to occurrence of NMSC will be calculated from the first visit to the development of an NMSC in the treatment areas and in the control areas.
- Pain control with Levulan-PDT in Solid Organ Transplant Recipient [ Time Frame: Day 1, Day 30, Day 180, 12 months, 18 months, 24 months, 30 months, 36 months ]Pain will be assessed on the 10 point Visual Analogue Scale (VAS), as mild (0-3), moderate (4-7) or severe (8-10). Patients will be asked to rate the pain at the beginning, midway point (approximately 8 minutes later), and at the end of each PDT session.
- The number of participants with treatment related adverse events as assessed by the CTCAE v4.0 [ Time Frame: 3 Years ]The number of evaluable study participants who had a grade 3 or higher adverse event (AE) or any serious adverse event that's determined to be at least possibly or probably related to study treatment, or any AE which is at least possibly or probably related to study treatment that causes permanent study discontinuation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Received solid organ transplant
- 3-24 months post-transplant (any number of transplant)
- Time interval of at least 6 days duration where complications such as rejection episodes, viral infections, surgical interventions and therapies with mono or polyclonal antibodies are ruled out by the transplant team.
- No prior history of NMSC in the treatment fields
- No AK/Bowen's disease in the treatment fields within the last 3 months.
- Moderate to severe sun damage
- Be willing to forego other interventions in the treatment fields than the ones approved by the investigator that would interfere with the protocol or evaluation of the study medication
Exclusion Criteria:
- Patients with Fitzpatrick's scale skin type IV-VI
- Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins
- Known sensitivity to any of the components of the Levulan® Kerastick® for Topical Solution
- Prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit
- Unable to return for follow-up visits and tests
- Any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03110159
| Contact: Nathalie C. Zeitouni, MD | (602) 354 5770 | rheeney@usdermparters.com | |
| Contact: Ryan Heeney | (602) 354 5770 ext 4248 | rheeney@usdermpartners.com |
| United States, Arizona | |
| Medical Dermatology Specialists | Recruiting |
| Phoenix, Arizona, United States, 85006 | |
| Contact: Ryan Heeney 602-354-5770 ext 4248 rheeney@usdermpartners.com | |
| Principal Investigator: Nathalie Zeitouni, MD | |
| Principal Investigator: | Nathalie C. Zeitouni, MD | Medical Dermatology Specialists |
Documents provided by Medical Dermatology Specialists:
| Responsible Party: | Medical Dermatology Specialists |
| ClinicalTrials.gov Identifier: | NCT03110159 |
| Other Study ID Numbers: |
PHXB-16-0142-80-15 MDS ( Other Identifier: Medical Dermatology Specialists ) |
| First Posted: | April 12, 2017 Key Record Dates |
| Last Update Posted: | May 4, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Photodynamic therapy Prevention Actinic Keratosis Skin Cancer |
Non-melanoma Skin Cancer Sun Damaged Skin Solid Organ Transplant PDT |
|
Keratosis, Actinic Skin Neoplasms Keratosis Skin Diseases Precancerous Conditions |
Neoplasms Neoplasms by Site Aminolevulinic Acid Photosensitizing Agents Dermatologic Agents |